# 1 Cost and availability of drugs and treatment regimens and availability of drug

# 2 resistance testing for tuberculosis in Europe

- 3
- 4 Authors:
- 5 Gunar Günther MD<sup>1,2</sup>, Lorenzo Guglielmetti MD<sup>3,4</sup>, Claude Leu MD<sup>1</sup>, Christoph Lange
- 6 MD<sup>5, 6, 7,8</sup>, Frank van Leth PhD<sup>9</sup> for TBnet\*
- 7

8 Affiliations:

- 9 <sup>1</sup> Department of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital,
- 10 University of Bern, Switzerland
- <sup>2</sup> Department of Medical Sciences, School of Medicine, University of Namibia, Windhoek,
- 12 Namibia
- <sup>3</sup> Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses,
- 14 Cimi-Paris, équipe 2, Paris, France
- 15 <sup>4</sup> APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière,
- 16 Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux
- 17 Antituberculeux, Paris, France.
- <sup>5</sup> Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
- 19 <sup>6</sup> German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems,
- 20 Borstel, Germany.
- 21 <sup>7</sup> Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- <sup>8</sup>Baylor College of Medicine and Texas Children's Hospital, Global TB Program, Houston, TX,
- 23 USA
- <sup>9</sup> Department of Health Sciences, VU University, Amsterdam, The Netherlands; Amsterdam
- 25 Public Health research institute, Amsterdam, The Netherlands
- 26 \*Contributors of TBnet participating in this study are listed in the acknowledgements

28

- 29 Corresponding author:
- 30 Gunar Günther MD, Department of Pulmonary Medicine and Allergology, Inselspital, Bern
- 31 University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland
- 32 Email: <a href="mailto:gunar.guenther@insel.ch">gunar.guenther@insel.ch</a>; phone: 0041 31 6321900

33

- 34 Word count total: 3269
- 35 Word count abstract: 200

# 37 Research in context:

38

#### 39 Evidence before this study

40 Availability and access to anti-tuberculous treatment are essential for optimal treatment 41 outcomes. Newly developed drugs like bedaquiline have demonstrated an enormous potential to improve outcomes, in particular for the treatment of drug-resistant 42 43 tuberculosis. However, data on availability and cost of tuberculosis drugs and regimens are 44 scarce. We searched PubMed for original research that reported the cost of anti-tuberculosis 45 drugs and regimens across multiple countries in the WHO European region since Jan 1, 2012. 46 The Pubmed search ((cost[MeSH Major Topic]) AND (tuberculosis[MeSH Major Topic]) AND 47 [(treatment[MeSH Major Topic]) OR (drug[MeSH Major Topic])] AND ("2012/01/01"[Date -48 Entry] : "3000"[Date - Entry])) did not reveal any comprehensive data on cost of antituberculosis drugs since the introduction of new (bedaquiline, delamanid, pretomanid) and 49 50 re-purposed drugs in the WHO European region. Recent information on availability of 51 Mycobacterium tuberculosis drug susceptibility testing is limited to a single, laboratory-52 based survey.

53

# 54 Added value of this study

55 Building on a previous study, performed by the Tuberculosis Network European Trialsgroup 56 (TBnet) in 2013, the current study documents a) the concerning lack of diagnostic capacity of 57 drug susceptibility testing for new and repurposed anti-tuberculosis drugs; b) the lack of 58 availability of adequate regimens for the treatment of multidrug-resistant and (pre-) 59 extensively drug-resistant tuberculosis, in particular in middle income countries; and c) the 60 enormous cost of regimens for the treatment of drug-resistant tuberculosis, in particular in 61 high-income countries.

62

#### 63 Implications of all the available evidence

The lack of availability of drug-resistance testing in the presence of new and re-purposed drugs bears the high risk of undetected amplification of *M tuberculosis* drug resistance. In addition, it implies that identification of patients with extensively drug-resistant tuberculosis is currently not possible in many countries in the WHO European region. The cost of drugs and regimens for drug-resistant tuberculosis treatment are very high compared to those for

drug-susceptible tuberculosis and highly variable across different countries. Access to
adequate treatment regimens for (pre-) extensively drug-resistant tuberculosis is
suboptimal.

Rapid upscaling of comprehensive *M tuberculosis* drug resistance testing and provision of novel anti-tuberculosis drugs are urgently required to provide patients affected by drugresistant tuberculosis with adequate treatment regimens and prevent the emergence of additional drug resistance in *M tuberculosis* naturally occurring under insufficient treatments.

#### 78 Abstract

*Background:* Access to comprehensive diagnostics and novel anti-tuberculosis medicines is
crucial to improve tuberculosis control at times of emerging *Mycobacterium tuberculosis*drug resistance.

82 *Methods:* We investigated access to genotypic and phenotypic *M tuberculosis* drug 83 susceptibility testing (DST), availability of anti-tuberculosis drugs and calculated cost of drugs 84 and treatment regimens at major tuberculosis treatment centers in countries of the World 85 Health Organization (WHO) European region. Results are stratified by middle and high-86 income countries.

87 *Results:* Overall, 43 treatment centers in 43 countries participated in the study. Phenotypic 88 DST was available for WHO group A drugs levofloxacin/moxifloxacin, bedaquiline and 89 linezolid, in 75%/82%, 48%, and 72% of countries, respectively. Overall, 84% and 56% of 90 countries had access to bedaquiline and delamanid, while only 14% had access to 91 rifapentine. Median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant 92 tuberculosis (shorter regimen, including bedaquiline for six months) and pre-extensively 93 drug-resistant tuberculosis (including delamanid) were €44, €764 and €7 094 in middle 94 income countries (n=12), and €280, €29 765, €207 035 in high income countries (n=29). 95 Conclusion: Tuberculosis control in Europe is limited by widespread lack of DST capacity to

96 new and re-purposed drugs, lack of access to essential medications and high treatment cost
97 for drug-resistant tuberculosis.

98

99

# 101 Introduction

Diagnostic improvements and availability of novel anti-tuberculosis medicines have brought 102 substantial change to the management of patients affected by drug-resistant tuberculosis.<sup>1,2</sup> 103 Molecular drug susceptibility testing (DST) based on nucleic acid amplification technologies 104 entered clinical routine in many countries.<sup>3</sup> New anti-tuberculosis drugs (i.e. bedaquiline, 105 106 delamanid and pretomanid) were approved for drug-resistant tuberculosis treatment along with fundamental changes in treatment guidelines and regimens.<sup>4</sup> Although with relevant 107 108 delays, phenotypic DST for new and re-purposed drugs (i.e. linezolid, clofazimine) are being developed.<sup>3</sup> Such innovations can improve tuberculosis control if they are accessible for 109 110 patients and programs. Improving access by ensuring affordable pricing of drugs is a crucial issue for all new anti-tuberculosis drugs, and a major topic of political debate and advocacv.<sup>5</sup> 111

112

113 Following a recent revision of the hierarchy of anti-tuberculosis drugs for the treatment of patients with drug-resistant tuberculosis by the World Health Organization (WHO) in 2020.<sup>6</sup> 114 115 little is known about the availability of drugs and DST for new and re-purposed antituberculosis drugs. The same holds true for cost of these drugs and treatment regimens.<sup>7,8</sup> 116 The Tuberculosis Network European Trialsgroup (TBnet), an European-based network 117 promoting TB research and training,<sup>9</sup> first evaluated the availability and cost of anti-118 tuberculosis drugs and regimens among 37 European countries in 2013.<sup>10</sup> at a time when 119 bedaquiline, delamanid and pretomanid were not yet available. In order to provide an 120 121 updated account on the availability of anti-tuberculosis DST and the costs and availability of anti-tuberculosis drugs and regimen, we performed a new survey among major treatment 122 123 centres and through TBnet referent physicians in the countries of the WHO European region.

124

#### 125 Methods

#### 126 Data collection

Data on tuberculosis drug availability, cost, and availability of DST for all anti-tuberculosis 127 128 drugs were surveyed administering a standardized questionnaire to TBnet representatives 129 with experience in the management of drug-resistant tuberculosis at referral treatment 130 centres in countries of the WHO European region. If no TBnet representatives were available 131 in a country, we searched Pubmed for major publications on drug-resistant tuberculosis and 132 approached respective authors from target countries. Data collection for cost and DST 133 availability was performed from June to December 2020 and updated in October 2021. The list of the drugs in the survey was developed with reference to those available via the global 134 drug facility.<sup>11</sup> 135

136

## 137 Data analysis

138 Drug cost calculations were based on available formulations and cost for one unit (tablet or 139 vial) of the drug. We determined the number of units required to provide adequate daily treatment for patients with 70 kg of body weight, according to WHO-recommended drug 140 doses.<sup>4</sup> When available, fixed dose combinations (FDC) were included in the calculation of 141 142 the regimen cost and the least-expensive regimen option was reported. Daily treatment cost 143 for drugs given on a non-daily basis, like bedaquiline, were based on weekly cost divided by 144 seven. Cost data were collected in local currency. If data were given in US dollars (USD), the 145 exchange rate as of 01.07.2020 was used to convert in local currency. Costs are reported in 146 Euro ( $\in$ ) when there is no direct between-country comparison. For direct between-country comparisons, drug cost were converted in international dollars (ID\$) using the purchasing 147 power parity conversion factor from the international comparison program 2017.<sup>12</sup> 148 149 Stratification according to income followed the World Bank classification, where upper and lower middle income countries are combined as middle income countries (figure S1).<sup>13</sup> Costs 150 of regimens and drugs are presented as median with minimum and maximum values, if not 151 152 otherwise stated.

153

We selected regimens for drug-susceptible tuberculosis (DS-TB), multidrugresistant/rifampicin-resistant tuberculosis (MDR/RR-TB), pre-extensively drug-resistant tuberculosis (pre-XDR TB), and extensively drug-resistant tuberculosis (XDR-TB) based on

latest guidelines from WHO<sup>4,14</sup>, and American Thoracic Society/Centers for Disease 157 158 Control/European Respiratory Society/Infectious Diseases Society of America (ATS/CDC/ERS/IDSA)<sup>15</sup>; regimen compositions are shown in table S1. DS-TB was defined as 159 susceptible to all first-line TB drugs. MDR/RR-TB, pre-XDR TB, and XDR-TB were defined 160 according to WHO 2020 definitions.<sup>16</sup> We hereby present results for eight priority regimens 161 162 (table 1). Results for additional regimens are available in the supplement (table S2). We did not present cost for a standardized regimen containing bedaquiline, linezolid and 163 pretomanid (BPaL)<sup>17</sup>, as the regimen is currently only recommended by WHO in the context 164 165 of operational research. DST availability was evaluated for the same list of drugs as cost data 166 and stratified by phenotypic and genotypic testing. In the questionnaire, clinicians were not 167 asked to specify whether DST was performed locally at the tuberculosis treatment centre.

168

169 Ethics

170 Ethical clearance was granted by the Institutional Review Board of Bligny Hospital, France

171 (January 15th, 2020; CRE 2020 01). As no patient data were collected, ethical board review

172 was not applicable at any of the participating centres.

#### 173 Results

#### 174 Survey response

175 The WHO European region has 53 countries (not including Kosovo). We excluded Central 176 Asian countries and small city countries (in total, n=8) from the survey and therefore did not 177 contact representatives from Andorra, Kazakhstan, Kyrgyzstan, Monaco, San Marino, 178 Tajikistan, Turkmenistan, and Uzbekistan. Overall, data on drug availability were obtained 179 and analysed from 43, data on drug cost from 41, and data on DST availability from 40 180 countries. We were unable to obtain responses on drug cost, availability, and DST availability 181 from Azerbaijan, Bosnia and Herzegovina, and Montenegro. Drug cost data were not 182 available from Malta and Israel. DST data were not available from Malta, Kosovo and 183 Iceland.

184

#### 185 Availability of DST

186 Phenotypic DST testing was generally more widely available than genotypic testing. While 187 phenotypic DST for all first-line drugs was available in 38/40 (95%) countries, genotypic DST 188 was available for rifampicin in 40/40 (100%) and for isoniazid in 38/40 (95%) countries, but 189 only in 21/40 (53%) for ethambutol and in 12/40 (30%) for pyrazinamide. For WHO Group A 190 drugs, the frequency of countries with availability of phenotypic and/or genotypic DST was as follows: 30/40 (75%) and 29/40 (73%) for levofloxacin, 33/40 (82%) and 32/40 (80%) for 191 192 moxifloxacin, 19/40 (48%) and 10/40 (25%) for bedaquiline, 29/40 (72%) and 11/40 (28%) 193 for linezolid, respectively (figure 1). For Group B drugs, the frequency of countries with 194 availability of phenotypic and/or genotypic DST was 25/40 (63%) and 11/40 (28%) for 195 clofazimine, and 23/40 (58%) and 8/40 (20%) for cycloserine/terizidone, respectively. Among Group C drugs, phenotypic and/or genotypic DST testing was only available in 6/40 (15%) 196 197 and 1/40 (2.5%) countries for carbapenems (meropenem and imipenem), and in 17/40 (42%) 198 and 10/40 (25%) for delamanid, respectively. Phenotypic DST for rifapentine could not be 199 evaluated in any of the countries and genotypic DST for this drug was only available in 6/40 200 (15%) countries. Similarly, phenotypic DST to pretomanid was only available in 2/40 (5%) and 201 genotypic DST in 4/40 (10%) of the countries, respectively.

202

## 203 Availability of tuberculosis drugs

204 The four first-line drugs rifampicin, isoniazid, pyrazinamide and ethambutol were available in 205 all 43 countries, as single drugs or as part of fixed-dose drug combinations. Levofloxacin and 206 moxifloxacin were available in 43/43 (100%) and 41/43 (95%), bedaquiline in 36/43 (84%) 207 and linezolid in 43/43 (100%) countries, respectively. Clofazimine was available in 35/43 208 (81%) countries, but only in 8/12 (67%) middle income countries. Delamanid was available in 209 24/43 (56%) countries. Meropenem and imipenem were available in 28/43 (65%) and 25/43 210 (58%) countries: access was in particular limited in middle income countries, where only 211 3/12 (25%) and 4/12 (33%) countries had access to the drugs, compared to 25/31 (81%) and 212 21/31 (68%) high income countries. Pretomanid was available only in 4/43 (9%) countries, all 213 high income countries. Only 6/43 (14%) countries reported access to rifapentine (table S4).

214

# 215 *Cost of tuberculosis drugs*

216 Tuberculosis drugs were generally less expensive in middle income countries, albeit there 217 was large variability in drug cost between countries. The drugs with the highest median daily 218 treatment costs were delamanid, bedaguiline, and rifagentine in high income countries and 219 imipenem, meropenem, and delamanid in middle income countries, respectively. Daily 220 median treatment costs for delamanid were €128.04 in high income countries, and €8.52 in 221 middle income countries, while for bedaquiline it was €103.98 and €1.60, respectively. The 222 daily median treatment cost of amikacin was €10.10 in high income countries and €1.18 in 223 middle income countries (table S4).

224

## 225 Availability of tuberculosis treatment regimens

Treatment of DS-TB according to current WHO guidelines was available in all 43 (100%) countries (table 1). The shorter MDR/RR-TB regimen with bedaquiline was available in 26/43 (60%) countries, while the conventional long MDR/RR-TB regimen was available in 31/43 (72%) countries. A pre-XDR TB treatment, with amikacin or delamanid replacing the fluoroquinolones, was available in 28/43 (65%) and 20/43 (47%) countries, respectively. Treatment of patients with XDR-TB with a regimen including a carbapenem was only available in 17/43 (40%) countries (tables 1 and S2).

233

# 234 Cost of tuberculosis treatment regimens

235 In general, regimens were considerably less expensive in middle income than in high income 236 countries. Figure 3 illustrates the direct comparison of the cost of treatment regimens 237 between countries, taking into account purchasing power parity based in ID\$. Figure 4 shows 238 the overall distribution of regimen costs, based on Euro. The median cost of a DS-TB regimen 239 was €44 in middle income countries and €280 in high income countries. The median cost of 240 the shorter MDR/RR-TB regimen with bedaguiline for 6 months was €764 in middle income 241 countries and €29 765 in high income countries, while the conventional long MDR/RR-TB 242 treatment regimen with bedaquiline for 6 months costed €2 214 and €51 617, respectively 243 (tables 1, S2 and S3). A pre-XDR TB treatment regimen using delamanid or amikacin costed 244 €7 094 or €2 250 in middle income countries, respectively, and €207 034 or €108 459 in high 245 income countries, respectively. A regimen for the treatment of patients with XDR-TB with 246 resistance to fluoroquinolones and linezolid, including bedaquiline, delamanid, and a 247 carbapenem costed €8 709 in middle income countries and €217 591 in high income 248 countries.

Overall, high costs for drug-resistant tuberculosis treatment regimens were driven by specific drugs, such as delamanid and carbapenems in middle income countries, and delamanid, bedaquiline, and to a lesser extent, para-aminosalycilic acid and cycloserine/terizidone in high income countries (table S4).

## 254 Discussion

255 Treatment of drug-resistant tuberculosis has undergone major changes recently due to 256 diagnostic and therapeutic breakthroughs, including the use of new and re-purposed drugs.<sup>4,15</sup> Following a first survey in 2013, we provide an updated report on the availability of 257 258 DST for anti-tuberculosis drugs, as well as the costs and availability of anti-tuberculosis drugs 259 in the WHO European region. The main finding of this survey is that availability of DST for 260 second-line anti-tuberculosis drugs, in particular new and re-purposed drugs, is severely 261 limited in Europe and that new drugs are more frequently available than their specific DST. 262 Cost of drugs and regimens for drug-resistant tuberculosis treatment are very high compared to treatment of DS-TB. In addition, the cost of regimens is highly variable across 263 264 different countries. Access to adequate treatment regimens for pre-XDR and XDR-TB is 265 limited, in particular in middle income countries. Finally, almost no country in Europe has 266 access to drugs included in new promising regimens for drug-susceptible and drug-resistant 267 tuberculosis, such as rifapentine and pretomanid.

268

269 Phenotypic DST remains the gold standard for the detection of drug resistance in M 270 tuberculosis. International guidelines for the management of drug-resistant tuberculosis 271 suggest including in a treatment regimen at least four effective drugs, ideally based on DST 272 results.<sup>4,15</sup> Our findings are very worrying: in 2021, only 75% and 82% of the countries in the 273 survey report phenotypic DST capacity for levofloxacin and moxifloxacin, 48% for 274 bedaquiline, and 72% for linezolid, while availability of these drugs is much higher. Hence, 275 physicians in many countries of the WHO European region use Group A drugs for MDR/RR-TB treatment without capacity to detect resistance against these drugs. Similar findings were 276 obtained by the network of European tuberculosis reference laboratories.<sup>18</sup> Phenotypic DST 277 278 for Group B drugs clofazimine and cycloserine/terizidone is available in less than 65% of the 279 countries, while only 42% of countries can test for delamanid resistance. In addition to the 280 lack of DST capacity, reliable data on clinical breakpoints, compounds for resistance testing and adequate strains for external quality control are still missing for some drugs, in 281 particular for the new drugs bedaguiline, delamanid and pretomanid.<sup>19</sup> Recent reports of 282 growing resistance to new and re-purposed drugs underline the need for resistance 283 detection and surveillance.<sup>20-22</sup> This is particularly important since resistance to Group A 284 drugs in particular is associated with worse MDR/RR-TB treatment outcomes.<sup>23,24</sup> 285

Globally, the implementation of the new WHO definition for XDR-TB is problematic.<sup>25,26</sup> The 286 definition of XDR-TB requires confirmed resistance for rifampicin, isoniazid, a 287 fluoroquinolone and at least another group A drug, linezolid and/or bedaquiline.<sup>16</sup> According 288 289 to our results, 52% of European countries cannot detect bedaguiline resistance and 27% 290 cannot detect linezolid resistance: as a consequence, the identification of patients with XDR-291 TB is not possible in the majority of countries in the region. As for other processes in 292 evolution, the main drivers of antimicrobial drug-resistance development are variation and 293 selection. In order to avoid treatment regimens that include ineffective medicines, which 294 might lead to emergence of further *M* tuberculosis drug resistance, comprehensive DST results must be available to treating physicians.<sup>2</sup> This poses enormous challenge to 295 296 detection, appropriate management and surveillance of XDR-TB in the WHO European 297 region, and even more so in other, resource-poor settings of the world. New genotypic DST 298 solutions, like Deeplex Myc-TB<sup>®</sup> (Genoscreen, Lille, France), may have the potential to improve rapid access to DST.<sup>27</sup> 299

300

301 All sites in the survey reported availability of treatment for DS-TB. However, as the number 302 of drugs to which the strain is resistant increases, the availability of suitable regimens 303 declined. Middle income countries have generally less resistance-appropriate treatment 304 options then high income countries. In the 2013 TBnet assessment on the availability of 305 regimens performed in 37 European countries, 81% of countries had access to adequate 306 MDR/RR-TB regimens (now 72%), 65% to a pre-XDR TB regimen (now 67%), and 35% to a XDR-TB regimen (now 42%). <sup>10</sup> Unfortunately, the access situation to the relevant regimens 307 308 seems fairly unchanged since the introduction of new drugs and regimens.

309

310 The limited availability of medicines for patients with MDR/RR-TB and even more with XDR-311 TB dramatically affects the quality of care of the 70 000 patients affected by MDR/RR-TB including 7 259 patients affected by XDR-TB notified in the WHO European region in 2019,<sup>28</sup> 312 313 whose treatment options remain limited. High cost of novel drugs for anti-tuberculosis 314 treatment regimens is restricting availability of these medicines for many of the affected 315 patients in this region. Based on the findings of this study, the drivers for limited access to TB 316 drugs and DST testing need further investigation and action. This process is already initiated 317 by WHO Regional Office for Europe (T. Humbert, personal communication). An analysis on

barriers and challenges to access TB medicines is being conducted, focussing first on EU
member states, to be concluded in 2022.

320

321 The drug treatment for a patient with MDR/RR-TB with the shorter regimen (including 6 322 months bedaquiline) costs approximately 18 times more in middle income countries and 106 323 times more in high income countries than the standardized DS-TB regimen. This has 324 enormous cost implications for health systems in countries with high burden of drug-325 resistant tuberculosis. For example, the Republic of Moldova (total population of 2.6 million 326 2020) reported 559 patients with MDR/RR-TB in 2019, corresponding to 73% of all incident 327 MDR/RR-TB patients notified of the whole European Union (763 patients in 28 countries/ total population of 447 million 2021).<sup>28</sup> 328

329

330 The global drug facility provides subsidized access to anti-tuberculosis drugs. Across the 331 WHO European region, 9 countries (including one high income country) report drug 332 procurement via the global drug facility. The shorter MDR/RR-TB regimen with 6 months 333 bedaquiline costs approximately €390 (€1 = USD 0.85) in 2021, using drugs purchased via the global drug facility.<sup>29</sup> In our study, the median costs for the same regimen were €764 and 334 335 €29 765 in middle income and high income countries, respectively. The barriers to 336 procurement via global drug facility are not clear and should be investigated and addressed 337 for eligible middle income countries.

338

339 Of note, high regimen costs in Europe are related to the high prices of tuberculosis drugs in 340 general, but are impacted in particular by the enormous cost of the new drugs bedaguiline 341 and delamanid. Recent data from Finland and Estonia confirm the very high cost contribution of the new drugs to regimen cost.<sup>7</sup> In Germany, for instance, the daily therapy 342 343 cost for bedaquiline is €133. Since July 2020 139 countries, including Eastern European 344 countries, are eligible to procure bedaquiline for  $\leq 1.27$  ( $\leq 1 = USD 0.85$ ) daily treatment cost via the global drug facility. In contrast, it was estimated that the generic production of 345 bedaguiline could lead to daily treatment cost of 0.21 - 0.48 per day.<sup>30</sup> Patent protection 346 for bedaguiline lasts at least until June 2023:<sup>29</sup> only then less expensive generic products 347 348 could be licensed. New patent applications by the manufacturer of bedaquiline could extent

349 the patent protection till 2027,<sup>29</sup> despite the fact that the public investments on bedaquiline

development exceed the originators company investments by a factor 1.6-5.1.<sup>30</sup>

351

Rifapentine has recently shown the potential to shorten DS-TB treatment when used in 352 353 combination with moxifloxacin, isoniazid and pyrazinamide as part of a four-month regimen<sup>31</sup> which was already endorsed by WHO.<sup>32</sup> In addition, rifapentine is also 354 355 recommended for tuberculosis prevention in the one month daily rifapentine/isoniazid (1HP) and three months weekly rifapentine/isoniazid (3HP) regimen.<sup>33</sup> Of concern, our 356 357 results show that rifapentine is only available in two middle income countries and four high 358 income countries in the European region. Rifapentine is not registered in the EU. The 359 manufacturer of rifagentine, an off patent protection drug, has withdrawn its patent 360 application with the European Patent Office for a fixed dose combination with isoniazid in 2019.<sup>34</sup> UNITAID, the Stop TB Partnership and the manufacturer announced in 2019 an 361 362 access programme for 3HP, which reduced the price of a three-month course of rifagentine 363 to approximately €13.86. Among the countries included in this survey, Russia, the Republic of Moldova and Ukraine were granted such access.<sup>35</sup> Access to rifapentine in Europe and 364 worldwide remains an urgent matter. This has been addressed very recently with an 365 366 invitation to manufacturers by the WHO to present rifagentine to the WHO pre-qualification 367 process.<sup>36</sup>

368

369 This study has several limitations. Most importantly, it is not fully representative of the 370 access and cost for DST, drugs and regimens in the WHO European region. Data are derived 371 only from a single site in each country, which was considered to represent the access and 372 cost situation in the country. We assumed that data informants were able to gather 373 representative information for their site, which would reflect the country-wide situation. 374 Hence, we refer to countries instead of individual sites within our analysis. Second, data 375 were predominantly obtained from clinicians treating drug-resistant tuberculosis. Data from 376 such a source might differ from data obtained from a national TB programme. Third, we did not analyse the role of possible stock outs on drug availability. Fourth, the choice of 377 regimens for cost calculations followed the recommendations of WHO <sup>4</sup> and 378 ATS/CDC/IDSA/ERS<sup>15</sup>, whereas other regimen compositions could also be possible. 379

380 Despite these weaknesses, the study provides first-hand insight about the access to DST,

drugs and related drug and regimen costs and should inform health policy decisions in the

- 382 context of the endTB strategy in Europe.<sup>37</sup>
- 383

In conclusion, data provided from this study call for urgent action. Availability of novel drugs and treatment regimens for patients affected by MDR/RR-TB is substantially limited in Europe. Even more limited is the DST capacity for second-line drugs, leading to uncontrolled use of new/re-purposed drugs and the risk of amplifying *M tuberculosis* drug-resistance. Strong political support and coordinated action from civil society, national tuberculosis programmes and non-governmental organizations is needed to ensure access to the best standard of care to patients affected by tuberculosis.

#### 392 Acknowledgements:

393

## 394 *Members of the TBnet study group*

395 We thank the following colleagues for the contribution of data to this analysis:

396 Hasan Hafizi (Tirana, Albania), Naira Khachatryan, Harut Aroyan, Eduard Kabasakalyan 397 (Yerevan, Armenia), Michael Knappik (Vienna, Austria), Alena Skrahina, Dzmitry Klimuk, 398 Alena Nikolenka (Minsk, Belarus), Inge Muylle (Brussels, Belgium), Vladimir Milanov, 399 Desislava Velkovska, Neli Tarinska, Elizabeta Bachiyska (Sofia, Bulgaria), Mateja Jankovic 400 (Zagreb, Croatia), Despo Pieridou, Tonia Adamide, Nicos Nicolaou (Nicosia, Cyprus), Martina 401 Vasakova, Marija Sukholytka, Emilia Kopeckà, Beata Polakova (Prague, Czech Republic), Aase 402 Bengard Anderson, Dorte Bek Folkvardsen, Erik Svensson (Copenhagen, Denmark), Manfred Danilovits, Tiina Kummik (Tartu, Estonia), Tuula Vasankari (Turku, Finland), Mathilde Fréchet-403 404 Jachym, Audrey Nahmiash (Briis-sous-Forges, France), Tamar Togonidze, Zaza Avaliani, Inga 405 Kinkladze, Rusudan Aspindzelashvili, Teona Bichashvili, Gulnazi Losaberidze, Tsitsino 406 Merabishvili (Tbilisi, Georgia), Barbara Kalsdorf (Borstel, Germany), Katerina Manika, 407 Karyofyllis Tsiakitzis (Thessaloniki, Greece), Agnes Bakos (Budapest, Hungary), Tinna Rán 408 Ægisdóttir, Guðrún Svanhvít Michelsen, Kristín Karlsdóttir (Reykjavik, Iceland), Anne-Marie McLaughlin, Margaret Fitzgibbon (Dublin, Ireland), Daniel Chemtob (Jerusalem, Israel), Luigi 409 410 R. Codecasa, Maurizio Ferrarese, Stefania Torri (Milano, Italy), Majlinda Gjocaj (Pristina, 411 Kosovo), Liga Kuksa (Riga, Latvia), Edita Davidaviciene (Vilnus, Lithuania), Gil Wirtz, Monique 412 Perrin (Luxembourg , Luxembourg), Analita Pace Asciak (Valetta, Malta), Dumitri Chesov 413 (Chisinau, Moldova), Wiel de Lange, Onno Akkerman (Groningen, Netherlands), Biljana 414 Illievska-Poposka (Skopje, North Macedonia), Ulrich Mack, Mogens Jesenius, Lajla Kvalvik, 415 Anne Torunn Mengshoel (Oslo, Norway), Katarzyna Kruzak (Krakow, Poland), Raquel Duarte, 416 Nadine Ribeiro (Porto, Portugal), Elmira Ibraim (Bucharest, Romania), Anna Kaluzhenina, 417 Olga Barkanova (Volgograd, Russia), Dragica Pesut (Belgrade, Serbia), Ivan Solovic (Vysne 418 Hagy, Slovakia), Petra Svetina (Golnik, Slovenia), Maria-Luiza de Souza-Galvão, Joan-Pau 419 Millet, Xavi Casas, Montserrat Vives (Barcelona, Spain), Judith Bruchfeld, Paulina Dalemo, 420 Jerker Jonsson (Stockholm, Sweden), Katrin Aeschbacher, Peter Keller (Bern, Switzerland), 421 Seref Ozkara (Ankara, Turkey), Simon Tiberi, Christabelle Chen (London, UK), Yana Terleeva 422 (Kiev, Ukraine) Andrii Dudnyk (Vinnytsia, Ukraine)

423

# 424 Author contributions:

- LG, GG, CLa and FvL designed the study, GG and CLe collected data, FvL and GG did the analysis, GG, CLa, LG, FvL drafted the manuscript and all authors reviewed and agreed on the final version for submission. Contributors of the TBnet study group approved the manuscript.
- 429

# 430 Role of funding source:

- 431 CLa is supported by the German Center for Infection Research (DZIF). All other authors have
- ano funding source in the context of this manuscript.
- 433

# 434 **Declaration of interest**:

- 435 LG is the co-Principal Investigator of two MSF-sponsored clinical trials testing shorter MDR-
- 436 TB regimens. He has no other competing interests to disclose. The other authors have no
- 437 conflict of interest to declare with regards to this work.
- 438

# 439 Data sharing statement:

- 440 Data on availability of drugs, DST and cost are available for sharing immediately after
- 441 publication for researchers with a sound proposal.
- 442
- 443

# 444 References

445 Dheda K, Gumbo T, Maartens G, et al. The Lancet Respiratory Medicine Commission: 1. 446 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of 447 multidrug-resistant and incurable tuberculosis. The Lancet Respiratory medicine 2019; 7(9): 448 820-6. 449 450 Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR, Jr. 2. 451 Management of drug-resistant tuberculosis. Lancet 2019; 394(10202): 953-66. 452 453 3. World Health Organization. Global tuberculosis report 2020, Licence: CC BY-NC-SA 454 3.0 IGO., 2020. 455 456 4. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: 457 treatment - drug-resistant tuberculosis treatment. World Health Organization; 2020. 458 Licence: CC BY-NC-SA 3.0 IGO., 2020. 459 460 5. MSF Access Campaign. DR-TB and TB prevention drugs under the microscope, 2020. 461 https://msfaccess.org/dr-tb-and-tb-prevention-drugs-under-microscope-7th-edition 462 (accessed 07.10.2021) 463 464 World Health Organization. WHO operational handbook on tuberculosis. Module 4: 6. 465 treatment - drug-resistant tuberculosis treatment. Geneva 2020. Licence: CC BY-NC-SA 3.0 466 IGO., 2020. 467 468 7. Feuth T, Patovirta RL, Grierson S, et al. Costs of multidrug-resistant TB treatment in 469 Finland and Estonia affected by the 2019 WHO guidelines. Int J Tuberc Lung Dis 2021; 25(7): 470 554-9. 471 472 8. Manalan K, Green N, Arnold A, et al. A cost comparison of amikacin therapy with 473 bedaquiline, for drug-resistant tuberculosis in the UK. J Infect 2020; 80(1): 38-41. 474 475 9. van Leth F, Brinkmann F, Cirillo DM, et al. The Tuberculosis Network European Trials 476 group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis 477 through European cooperation. *Eur Respir J* 2019; 53(1):1802089. 478 479 480 10. Günther G, Gomez GB, Lange C, Rupert S, van Leth F, Tbnet. Availability, price and 481 affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J 2015; 45(4): 482 1081-8. 483 484 11. Global Drug Facility. Medicine Catalogue 2020. 485 https://www.stoptb.org/sites/default/files/gdfmedicinescatalog 1.pdf (accessed 486 20.10.2021). 487 488 World Bank. Purchasing Power Parities and the Size of World Economies: Results 12. 489 from the 2017 International Comparison Program. Washington, DC: World Bank. DOI: 490 10.1596/978-1-4648-1530-0. License: Creative Commons Attribution CC BY 3.0 IGO, 2017. 491

492 13. World Bank. World Bank Country and Lending Groups 2021. 493 https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-494 and-lending-groups (accessed 13.08.2021). 495 496 World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis 14. 497 and patient care, 2017 update. Geneva: World Health Organization; 2017. Licence: CC BY-498 NC-SA 3.0 IGO., 2017. 499 500 Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An 15. 501 Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 502 2019; 200(10): e93-e142. 503 504 16. Viney K, Linh NN, Gegia M, et al. New definitions of pre-extensively and extensively 505 drug-resistant tuberculosis: update from the World Health Organization. *Eur Respir J* 2021; 506 57(4):2100361. 507 508 17. Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant 509 Pulmonary Tuberculosis. N Engl J Med 2020; 382(10): 893-902. 510 511 18. Faroog HZ, Cirillo DM, Hillemann D, et al. Limited Capability for Testing 512 Mycobacterium tuberculosis for Susceptibility to New Drugs. Emerg Inf Dis 2021; 27(3): 985-513 7. 514 515 19. Köser CU, Maurer FP, Kranzer K. 'Those who cannot remember the past are 516 condemned to repeat it': Drug-susceptibility testing for bedaquiline and delamanid. Int J 517 Infect Dis 2019; 80S: S32-S5. 518 519 20. He W, Liu C, Liu D, et al. Prevalence of Mycobacterium tuberculosis resistant to 520 Bedaquiline and Delamanid in China. J Glob Antimicrob Resist 2021;26:241-248. 521 522 21. Lee T, Lee SJ, Jeon D, et al. Additional Drug Resistance in Patients with Multidrug-523 resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019. J Korean Med Sci 524 2021; 36(26): e174. 525 526 22. Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and 527 clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in 528 southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe 2020; 1(4): e165-529 e74. 530 531 Roelens M, Battista Migliori G, Rozanova L, et al. Evidence-based Definition for 23. 532 Extensively Drug-Resistant Tuberculosis. Am J Resp Crit Care Med 2021; 204(6): 713-22. 533 534 Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic 24. 535 characteristics and clinical outcomes of resistance to bedaquiline in patients treated for 536 rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Inf Dis 537 2021; \$1473-3099(21)00470-9. 538 539

540 25. Alagna R, Cabibbe AM, Miotto P, et al. Is the new WHO definition of extensively drug-541 resistant tuberculosis easy to apply in practice? Eur Respir J 2021; 58(1):2100959. 542 543 26. Veziris N, Bonnet I, Morel F, et al. Impact of the revised definition of extensively drug 544 resistant tuberculosis. Eur Respir J 2021; 58(2): 2100641. 545 546 27. Jouet A, Gaudin C, Badalato N, et al. Deep amplicon sequencing for culture-free 547 prediction of susceptibility or resistance to 13 anti-tuberculous drugs. *Eur Respir J* 2021; 548 57(3): 2002338. 549 550 28. WHO/ECDC. Tuberculosis Surveillance and monitoring in Europe 2021 - 2019 data. 551 2021. https://www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-552 monitoring-europe-2021-2019-data(accessed 07.10.2021). 553 554 29. MSF Access Campaign. DR-TB and TB prevention drugs under the microscope, 2019. 555 https://msfaccess.org/dr-tb-and-tb-prevention-drugs-under-microscope-6th-edition 556 (accessed 07.10.2021). 557 558 30. Gotham D, Fortunak J, Pozniak A, et al. Estimated generic prices for novel treatments 559 for drug-resistant tuberculosis. Journal Antimicrob Chemother 2017; 72(4): 1243-52. 560 561 31. Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifagentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384(18): 1705-18. 562 563 564 32. World Health Organization. Treatment of drug- susceptible tuberculosis - rapid 565 communication. 2021. https://www.who.int/publications/i/item/9789240028678 (accessed 566 07.10.2021). 567 568 33. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: 569 prevention – tuberculosis preventive treatment. Geneva; 2020. Licence: CC BY-NC-SA 3.0 570 IGO. 571 572 34. Treatment Action Group. Isoniazid/Rifapentine (3HP) Access Roadmap and Patent 573 Landscape. 2020. https://www.treatmentactiongroup.org/wp-574 content/uploads/2020/03/3hp access roadmap and patent landscape.pdf (accessed 575 07.10.2021). 576 577 35. Stop TB Partnership and The Global Fund. Rifapentine Global Price Discount. 2019. https://www.impaact4tb.org/wpcontent/uploads/2019/11/Rifapentine Global Price Disco 578 579 unt Communique.pdf (accessed 07.10.2021). 580 581 36. World Health Organization. New Invitation for Expression of Interest (EOI) to 582 manufacturers of antituberculosis medicines published. 2021. 583 https://extranet.who.int/pgweb/news/new-invitation-expression-interest-eoi-584 manufacturers-antituberculosis-medicines-published (accessed 20.07.2021). 585 586

- 587 37. World Health Organization. The WHO End TB Strategy, 2015.
- 588 https://www.who.int/tb/strategy/End\_TB\_Strategy.pdf (accessed 20.11.2021).

589


590

<b>Table 1:</b> Availability and cost of drug regimens for the treatment of tuberculosis in countries in the
WHO Europe region, stratified by world bank income classification*, in Euros.

	M	liddle incon	ne country		High income country					
Regimen <sup>+</sup>	Availability	Availability Cost				Availability Cost				
	N (%)	median	min	max	N (%)	median	min	max		
DS -TB	12 (100)	44	15	152	31 (100)	280	78	1 084		
MDR/RR-TB short, Bdq 6 months‡	6 (50·0)	764	542	15 152	20 (64·5)	29 765	11 116	40 584		
MDR/RR-TB long, Bdq 18 months‡	7 (58·3)	2 954	1591	42477	24(77·4)	97 808	34 142	216 595		
pre-XDR TB, using Dlm	5 (42·7)	7 094	6 755	10 916	15 (48·4)	207 034	63 987	313 566		
pre-XDR TB, using Am	4 (33·3)	2 250	2 007	3 298	24 (77·4)	108 459	37 412	249 560		
XDR-TB, resistant Fq, Bdq, using a carbapenem <sup>#</sup>	4 (33·3)	7 945	6 981	11 221	13 (41·9)	141 307	40 237	255 550		
XDR-TB, resistant Fq, Lzd, using a carbapenem <sup>#</sup>	4 (33·3)	8 709	7 965	11 759	12(38·7)	217 591	82 827	320 146		
XDR-TB, resistant Fq, Bdq, Lzd, using a carbapenem <sup>#</sup>	4 (33·3)	8 348	6 949	11 528	10(32·3)	147 959	118 825	271 343		


\*drug availability data are from 43 countries, regimen cost calculation is based on data from 41 countries, not including Malta and Israel (both high income); †detailed regimen composition is depicted in table S1; ‡refers to the length of bedaquiline treatment; #refers to use of cheapest available carbapenem (meropenem or imipenem); DS-TB – drug-susceptible tuberculosis, MDR/RR-TB – multidrug-resistant/rifampicin-resistant tuberculosis, pre-XDR TB - pre-extensively drug-resistant tuberculosis, XDR-TB - extensively drug-resistant tuberculosis, Bdq - bedaquiline, DIm - delamanid, Fq - fluorquinolone, Am - amikacin, Lzd - linezolid.

**Figure 1:** Availability of phenotypic and genotypic drug susceptibility testing to tuberculosis drugs in countries in the WHO European region\*, in %.



\*n=40 countries; Kosovo, Iceland and Israel did not provide data on availability of drug susceptibility testing


**Figure 2:** Proportion of countries with availability of bedaquline, linezolid, clofazimine, and delamanid, but absence of drug susceptibility testing for those drugs\*.



\*n=40 countries; Kosovo, Iceland and Israel did not provide data on availability of drug susceptibility testing


Bdq - bedaquiline, Lzd – linezolid, Cfz – clofazimine, Dlm – delamanid,

**Figure 3:** Cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicinresistant tuberculosis using the shorter regimen for nine months with six months of bedaquiline, multidrug-resistant/rifampicin-resistant tuberculosis with the long conventional regimen with six months of bedaquiline, and extensively drug-resistant tuberculosis with resistance to fluoroquinolones, linezolid, and bedaquiline, stratified by country and income classification of world bank\*<sup>†</sup>, in international dollars (ID\$).



\* n=41 countries, Malta and Israel (both high income) did not provide data on drug cost; <sup>+</sup> detailed regimen composition in table S1; DS-TB – drug susceptible TB, MDR/RR - multidrug-resistant/rifampicin-resistant tuberculosis, XDR - extensively drug-resistant tuberculosis, Fq – fluoroquinolones, Bdq - bedaquiline, Lzd – linezolid.

**Figure 4:** Density graph of distribution\* of cost for tuberculosis drug regimens in the WHO Europe region, according to resistance status and world bank income classification<sup>†</sup> (high income countries in red, middle income countries in green), in Euros.




\* The density graph illustrates the distribution of the cost within a given resistance pattern. The area under the curve is scaled to one (1). The height in the distribution shows the range of the cost for the majority of countries. The width of the graph shows the range of the costs observed.

<sup>†</sup> n=41 countries, Malta and Israel (both high income) did not provide data on drug cost HIC – high income countries, MIC – middle income countries, DS-TB - drug susceptible TB, MDR/RR-TB – multidrug-resistant/rifampicin-resistant tuberculosis, pre-XDR TB – preextensively drug-resistant tuberculosis, XDR-TB – extensively drug-resistant tuberculosis, Bdq - bedaquiline, Fq - fluoroquinolones, Lzd - linezolid, Dlm – delamanid, Am – amikacin.

# Supplement:

**Figure S1: Countries represented in the survey** (high income countries: *Austria, Belgium, Croatia, Czech Republic, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary*, Iceland, *Ireland*, Israel, *Italy, Latvia, Lithuania, Luxemburg, Netherlands*, Norway, *Spain, Poland, Portugal, Romania Slovakia, Slovenia, Sweden*, Switzerland, United Kingdom; upper-middle income countries: Albania, Armenia, Belarus, *Bulgaria*, Georgia, Kosovo, North Macedonia, Russia, Serbia, Turkey, lower middle income: Republic of Moldova, Ukraine. In italic: member states of the European Union.)



Regimen	Н	hdH	R	Lfx	Bdq	Lzd	Cfz	Cs	Eto/Pto	Am	Mpm/Amx- Clv	Dlm	Z	E	PAS	Total duration
											- Clv					
$DS-TB^{\dagger}$	6		6										2	2		6
MDR/RR-TB short, Bdq 6 or 9 months <sup>†</sup>		4		9	6/9 *		9		4				9	9		9
MDR/RR-TB long, Bdq 6 or 18 months <sup>†</sup>				18	6/ 18*	18	18	18								18
pre-XDR TB, using Dlm <sup>†</sup>					20	20	20	20				20				20
pre-XDR TB, using Am <sup>†</sup>					20	20	20	20		6						20
XDR-TB, resistant Fq, Bdq, using carbapenem <sup>†</sup>						20	20	20	20		6	20				20
XDR-TB, resistant Fq, Bdq, using Am						20	20	20	20	6		20				20
XDR-TB, resistant Fq, Lzd, using carbapenem <sup>†</sup>					20		20	20	20		6	20				20
XDR-TB, resistant Fq, Lzd, using Am					20	20	20	20		6		20				20
XDR-TB, resistant Fq, Bdq, Lzd, using carbapenem <sup>†</sup>							20	20	20		6	20			20	20
XDR-TB, resistant Fq, Bdq, Lzd using Am							20	20	20	6		20			20	20

# Table S1: Regimen composition and treatment duration (months) by drug according to drug resistance (dosing for a patient with 70 kg body weight).

Abbreviation and dose (once daily if not indicated otherwise), per drug: H - isoniazid 300 mg/d, hdH - isoniazid 600 mg/d; R - rifampicin 600 mg/d; Lfx - levofloxacin 1000 mg/d; Bdq - bedaquiline 200 mg thrice weekly; Lzd - linezolid 600 mg/d, Cfz - clofazimine 100 mg/d; Cs - cycloserine 750 mg/d, Eto/Pto - ethionamide/prothionamide 1000 mg/d; Am - amikacin 1000 mg/d; Mpm/Amx-Clv - meropenem 3 g/d plus amoxicillin/clavulanic acid 3.6 g/d; Dlm - delamanid 200 mg/d; Z - pyrazinamide 2000 mg/d, E - ethambutol 1200 mg/d; PAS - para-amino salicylic-acid 12 g/d.

\*indicates alternatives in duration of treatment with bedaquiline; <sup>†</sup>indicates regimen presented in the main paper, cost for remaining regimens are in supplement; DS-TB – drug susceptible tuberculosis, MDR/RR-TB – rifampicin-resistant/multidrug-resistant tuberculosis, pre-XDR-TB – pre-extensively drug-resistant tuberculosis, XDR-TB – extensively drug-resistant tuberculosis, Fq - fluoroquinolones (moxifloxacin or levofloxacin), carbapenem (meropenem or imipenem).

		Middle inco	me countries	High income countries						
	Availability		Cost		Availability	Cost				
Regimen	N (%)	median	min	max	N (%)	median	min	max		
MDR/RR-TB short, Bdq 9 months <sup>†</sup>	6 (50.0)	815	582	17 040	20 (64.5)	33 087	12 422	45 035		
$\begin{array}{c} \text{MDR/RR-TB} \\ \text{long, Bdq 6} \\ \text{months}^{\dagger} \end{array}$	7 (58·3)	2 214	962	16 255	24 (77.4)	51 671	16 284	178 588		
XDR-TB, resistant Fq, Bdq, using Am	4 (33·3)	6 424	6 233	8 221	14 (45·2)	128 873	34 405	262 804		
XDR-TB, resistant Fq, Lzd using Am	4 (33·3)	7 216	7 175	8 758	13 (41.9)	203 644	62 955	327 399		
XDR-TB, resistant Fq, Bdq, Lzd using Am	4 (33·3)	6 832	6 206	8 527	11 (35-5)	147 035	43 596	278 597		

Table S2: Availability and cost of additional regimens for MDR/RR- TB and XDR- TB treatment in countries the WHO Europe region, stratified by world bank income classification<sup>\*</sup>, in Euros.

<sup>\*</sup>drug availability data are from 43 countries; regimen cost calculation is based on data from 41 countries, not including Malta and Israel (both high income); <sup>†</sup>refers to the length of bedaquiline treatment; Fq - fluoroquinolone, Bdq - bedaquiline, Am - amikacin, Lzd - linezolid, MDR/RR-TB - multidrug-resistant/rifampicin-resistant tuberculosis, XDR-TB - extensively drug-resistant tuberculosis.

	Mid	dle income coun	tries	High income countries					
		Cost		Cost					
Regimen*	median	min	max	median	min	max			
DS-TB	141	68	504	371	145	1 279			
MDR/RR-TB short, Bdq for 6 months <sup>‡</sup>	2 891	1 984	42 785	39 644	21 347	60 616			
MDR/RR-TB short, Bdq for 9 months $\ddagger$	3 088	2 129	48 118	44 366	23 709	67 547			
MDR/RR-TB long, Bdq for 6 months <sup>‡</sup>	7 616	4 081	45 903	70 821	29 903	210 664			
MDR/RR-TB long, Bdq for 18 months <sup>‡</sup>	10 162	6 094	119 949	128 103	62 697	255 498			
pre-XDR TB, using Dlm	31 348	25 597	45 128	235 913	117 503	438 633			
pre-XDR TB, using Am	10 023	7 343	11 343	146 910	68 703	294 385			
XDR-TB, resistant Fq Bdq, using Carbapenem <sup>#</sup>	32 926	29 656	38 597	160 755	64 211	301 450			
XDR-TB, resistant Fq, Bdq, using Am	27 912	23 557	28 924	152 969	58 149	310 007			
XDR-TB, resistant Fq Lzd, using Carbapenem <sup>#</sup>	36 831	32 447	40 444	260 272	167 416	377 648			
XDR-TB, resistant Fq Lzd, using Am	30 478	26 378	33 516	248 325	115 609	386 204			
XDR-TB, resistant Fq Bdq, Lzd, using Carbapenem <sup>#</sup>	33 496	31 501	39 651	175 027	155 533	320 080			
XDR-TB, resistant Fq Bdq, Lzd using Am	28 839	25 402	29 330	162 600	80 059	328 637			

# Table S3: Cost of regimen for susceptible TB, MDR/RR- TB, pre-XDR TB and XDR- TB in countries in the WHO Europe region, stratified by world bank income classification<sup>†</sup>, in ID\$.

<sup>\*</sup>detailed regimen composition depicted in table S1; <sup>†</sup>drug cost were obtained in 41 countries, not including Malta and Israel; <sup>‡</sup>refers to the length of bedaquiline (Bdq) treatment; <sup>#</sup> Carbapenem, refers to use of cheapest available carbapenem (Meropenem or Imipenem); MDR/RR-TB –multidrug-resistant/rifampicin-resistant tuberculosis, pre-XDR TB – pre-extensively drug-resistant tuberculosis, XDR-TB – extensively drug-resistant tuberculosis, Fq - fluoroquinolone, Dlm - delamanid, Am - amikacin, Lzd - linezolid.

Table S4: Cost of individual TB drugs per treatment day for a model patient with 70kg body weight, in
countries in the WHO Europe region <sup>*†</sup> , in Euros.

		Middle in	come countri	ies	High income countries						
Drug name	Drug available, N of countries	Cost data available, N of countries		ndividual d atment of patient		Drug available, N of countries	Cost data available, N of countries	Cost of individual drug for daily treatment of a 70 kg patient			
			median	min	max			median	min	max	
First line											
Rifampicin**	10	10	0.19	0.03	0.41	31	29	0.65	0.18	2.94	
Isoniazid	12	12	0.05	0.01	0.12	31	29	0.80	0.08	11.07	
Pyrazinamide	12	12	0.12	0.04	0.84	31	28	0.76	0.16	2.80	
Ethambutol	12	12	0.15	0.06	0.48	31	29	0.72	0.09	4.71	
Group A											
Bedaquiline <sup>‡</sup>	9	9	1.60	1.30	62.26	27	25	103.98	36.55	150-95	
Linezolid	12	12	1.85	0.16	25.65	31	29	17.03	1.00	91.43	
Moxifloxacin	11	11	0.21	0.08	2.33	30	28	1.59	0.39	11.54	
Levofloxacin	12	12	0.14	0.01	1.44	31	29	2.28	0.34	108.86	
Group B											
Terizidone <sup>#</sup>	2	2	4.74	3.59	5.88	9	9	39.60	18.00	67.98	
Cycloserine <sup>#</sup>	11	11	0.66	0.48	6.81	25	23	15.90	2.07	280.14	
Clofazimine	8	8	0.75	0.41	11.10	27	25	2.23	0.15	3.76	
Group C											
Delamanid	6	6	8.52	8.04	83-48	18	16	128.04	12.92	190-56	
Meropenem	3	3	8.88	5.79	16.68	25	24	26.91	7.77	126-09	
Imipenem	4	4	14.64	10.28	17.36	21	19	23.40	8.28	127.48	
Amoxicillin/ Clavulanic acid	7	7	0.20	0.15	0.81	29	26	0.63	0.15	5.88	
Streptomycin	2	2	0.20	0.02	0.39	15	11	6.50	0.90	76.79	
Amikacin	7	7	1.18	0.26	2.76	30	28	10.10	2.42	246.76	
Ethionamide <sup>§</sup>	3	3	0.40	0.32	0.80	13	10	28.36	4.40	33-48	
Prothionamide <sup>§</sup>	8	8	0.36	0.28	1.84	14	14	5.36	0.76	9.68	
PAS acid	8	5	2.46	0.24	3.72	15	15	49.17	24.81	74.79	
PAS salt	8	5	3.78	2.46	17.94	2	2	46.02	27.81	64·23	
Other											
Rifabutin	2	1	1.56	1.56	1.56	25	22	7.40	3.18	23.56	
Rifapentine	2	2	3.18	3.12	3.24	4	3	52.26	4.80	53.10	
Pretomanid	0	0				4	3	33.02	27.90	44.62	
Capreomycin	6	6	2.77	1.64	3.08	14	11	43.77	3.22	97.00	
Kanamycin	5	5	2.16	0.52	4.00	5	3	31.80	5.56	31.80	

<sup>\*</sup>drug availability data are from 43 countries, drug cost calculation is based on data from 41 countries, not including Malta and Israel; <sup>†</sup>daily drug dosage used for calculation of treatment cost: isoniazid 300 mg/d; rifampicin 600 mg/d; pyrazinamide 2000 mg/d; ethambutol 1200 mg/d; bedaquiline 200 mg 3x week; linezolid 600 mg/d; levofloxacin 1000 mg/d; moxifloxacin 400 mg/d; clofazimine 100 mg/d; cycloserine/terizidone 750 mg/d; delamanid 200 mg/d; imipenem 2000 mg/ d; meropenem 3000 mg/d; amoxicillin/clavulanic acid 1500/375 mg/d or 3000/600 mg (depending on availability); streptomycin 1000 mg/d; amikacin 1000 mg/d; ethionamide/prothionamide 1000 mg/d; PAS acid /PAS sodium salt 12 g/d; rifabutin 300 mg/d; rifapentine 900

mg/d; pretomanid 200 mg/d; capreomycin 1000 mg/d; kanamycin 1000 mg/d; <sup>‡</sup>bedaquiline 200 x 3 weekly: daily cost calculated as (200 mg x 3)/7 to estimate daily treatment cost; <sup>#</sup>cycloserine or terizidone are available in 11 (25.6%) middle income countries and 30 (69.7%) high income countries; <sup>§</sup>protionamide or ethionamide are available in 9 (20.9%) middle income countries and 24 (55.8%) high income countries; <sup>\*\*</sup>rifampicin was available only as fixed dose combination in Albania and Kosovo.